Brokerages predict that Ampio Pharmaceuticals, Inc. (NASDAQ:AMPE) will post earnings per share (EPS) of ($0.03) for the current quarter, according to Zacks. Zero analysts have made estimates for Ampio Pharmaceuticals’ earnings. Ampio Pharmaceuticals reported earnings of $0.09 per share during the same quarter last year, which indicates a negative year over year growth rate of 133.3%. The company is scheduled to issue its next earnings results on Monday, March 16th.

On average, analysts expect that Ampio Pharmaceuticals will report full year earnings of ($0.13) per share for the current year. For the next year, analysts expect that the business will post earnings of ($0.09) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Ampio Pharmaceuticals.

Separately, Roth Capital reiterated a “buy” rating on shares of Ampio Pharmaceuticals in a research note on Wednesday, December 18th.

AMPE remained flat at $$0.69 during mid-day trading on Friday. 442,235 shares of the company’s stock were exchanged, compared to its average volume of 1,337,230. The company’s 50-day moving average price is $0.65. Ampio Pharmaceuticals has a 1-year low of $0.26 and a 1-year high of $1.31.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee.

Featured Article: Google Finance Portfolio

Get a free copy of the Zacks research report on Ampio Pharmaceuticals (AMPE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with's FREE daily email newsletter.